HRT and breast cancer risk: A clue for interpreting the available data

Maturitas

Volumn 33, Issue 3, 1999, Pages 185-190

  Campagnoli, C ^a   Biglia, N ^b   Cantamessa, C ^a   Lesca, L ^a   Sismondi, P ^b  

^a Ospedale Sant'Anna   (Italy)

^b Cattedra Ginecol Oncologica Dell'U   (Italy)

Author keywords

Body weight; Breast cancer; Hormone replacement therapy (HRT); Insulin like growth factor I (IGF I); Progestins; Sex hormone binding globulin (SHBG)

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN; NANDROLONE DERIVATIVE; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN C;

ARTICLE; BODY MASS; BREAST CANCER; CANCER RISK; FEMALE; HORMONE SUBSTITUTION; HUMAN; OBESITY; ORAL DRUG ADMINISTRATION;

BODY WEIGHT; BREAST NEOPLASMS; EPIDEMIOLOGIC STUDIES; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; OBESITY; PROGESTINS; RISK FACTORS;

EID: 0032751469     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(99)00082-1     Document Type: Article

References (31)

1. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 without breast cancer. Lancet. 350:1997;1047-1059.
2. Kennedy D.L., Baum C., Forbes M.B. Noncontraceptive estrogens and progestins: use patterns over time. Obstet. Gynecol. 65:1985;441-446.
3. Pujol P., Galtier-Dereure F., Bringer J. Obesity and breast cancer risk. Hum. Reprod. 12:1997;116-125.
4. Colditz G.A. Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. J. Natl. Cancer. Inst. 90:1998;814-823.
5. Campagnoli C., Biglia N., Belforte P. et al. Post-menopausal breast cancer risk: oral estrogen treatment and abdominal obesity induce opposite changes in possibly important biological variables. Eur. J. Gynaecol. Oncol. 13:1992;139-154.
6. Kazer R.R. Insulin resistance, insulin-like growth factor I and breast cancer: a hypothesis. Int. J. Cancer. 62:1995;403-406.
7. Kaaks R. Nutrition, hormones, and breast cancer: is insulin the missing link? Cancer Causes Control. 7:1996;605-625.
8. Talamini R., Franceschi S., Favero A. et al. Selected medical conditions and risk of breast cancer. Br. J. Cancer. 75(11):1997;1699-1703.
9. Hankinson S.E., Willett W.C., Colditz G.A. et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet. 351:1998;1393-1396.
10. Nachtigall E.E. Sex hormone-binding globulin and breast cancer risk. Prim. Care update ob/gyns. 6/2:1999;39-45.
11. Stevenson J.C. The metabolic and cardiovascular consequences of HRT. Br. J. Clin. Pract. 49:1995;87-90.
12. Campagnoli C., Biglia N., Peris C., Sismondi P. Potential impact on breast cancer risk of circulating insulin-like growth factor I modifications induced by oral HRT in menopause. Gynecol. Endocrinol. 9:1995;67-74.
13. Weissberger A.J., Ho K.K.Y., Lazarus L. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women. J. Clin. Endocrinol. Metab. 72:1991;374-381.
14. Helle S.I., Omsjo I.H., Cwyfan Hughes S.C. et al. Effects of oral and transdermal oestrogen replacement therapy on plasma levels of insulin-like growth factors and IGF binding proteins 1 and 3: a cross-over study. Clin. Endocrinol. 45:1996;727-732.
15. Campagnoli C., Biglia N., Cantamessa C. et al. Insulin-like growth factor I (IGF-I) serum level modifications during transdermal estradiol treatment in postmenopausal women: a possible bimodal effect depending on basal IGF-I values. Gynecol. Endocrinol. 12:1998;259-266.
16. Newcomb P.A., Longnecker M.P., Storer B.E. et al. Long-term hormone replacement therapy and risk of breast cancer in post-menopausal women. Am. J. Epidemiol. 142:1995;788-795.
17. Colditz G.A., Hankinson S.E., Hunter D.J. et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N. Engl. J. Med. 332:1995;1589-1593.
18. Stanford J., Weiss N., Voigt L. et al. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. J. Am. Med. Assess. 274:1995;137-142.
19. Ewertz M. Influence of non-contraceptive exogenous and endogenous sex hormone on breast cancer risk in Denmark. Int. J. Cancer. 42:1988;832-838.
20. Persson I., Yuen J., Bergkvist L., Schairer C. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy-long-term follow-up of a Swedish cohort. Int. J. Cancer. 67:1996;327-332.
21. Persson I., Thurriel E., Bergström R., Holmberg L. Hormone replacement therapy and the risk of breast cancer: nested case-control study in a cohort of Swedish women attending mammography screening. Int. J. Cancer. 72:1997;758-761.
22. Køster A. Hormone replacement therapy: use patterns in 51-year-old Danish women. Maturitas. 12:1990;345-356.
23. Magnusson C., Baron J.A., Correia N. et al. Breast-cancer risk following long-term oestrogen- or oestrogen-progestin-replacement therapy. Br. J. Cancer. 81:1999;339-344.
24. Jeng M.H., Parker C.J., Jordan V.C. Estrogenic potential of progestins in oral contraceptives to stimulate human breast cancer cell proliferation. Cancer. Res. 52:1992;6539-6546.
25. Campagnoli C., Biglia N., Lanza M.G. et al. Hepatocellular effects of progestogens used in hormone replacement treatment and breast cancer risk. Genazzani A.R., Petraglia F., Genazzani A.D. Frontiers in Gynecologic and 26 Obstetric Investigation. 1993;345-353 Parthenon Publishing, Carnforth, UK.
26. Campagnoli C., Biglia N., Cantamessa C. et al. Effect of progestins on IGF-I serum level in estrogen-treated postmenopausal women. Zent. Gynäkol. 119:1997;7-11.
27. Goodman-Gruen D., Barrett-Connor E. Effect of replacement estrogen on insulin-like growth factor-I in postmenopausal women: the Rancho Bernardo Study. J. Clin. Endocrinol. Metab. 81:1996;4268-4271.
28. Cline J.M., Soderqwist G., von Schoultz E. et al. Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques. Am. J. Obstet. Gynecol. 174:1996;93-100.
29. Musgrove E.A., Sutherland R.L. Steroidal control of cell proliferation in the breast and breast cancer. Wren B.G. Progress in the management of the menopause. 1997;194-202 Parthenon Publishing, Carnforth, UK.
30. Wren B.G., Eden J.A. Do progestogens reduce the risk of breast cancer? a review of the evidence. Menopause. 3:1996;4-12.
31. Pasqualini J.R. Role, control and expression of estrone sulfatase and 17-β-hydroxysteroid dehydrogenase activities in human breast cancer. Zent. Gynäkol. 119:1997;48-53.